Impurity Reference Standard Development
Impurity Reference Standard Development is the systematic process of creating and validating authentic chemical specimens of impurities for use as benchmarks in the identification, characterization, and quantification of unintended components within pharmaceutical substances and products.
22
Publications
818
Citations
121
Authors
53
Institutions
Publications per year
2017–2026
5
22
PBDD/F impurities in some commercial deca-BDE
Man Ren, Ping’an Peng, Ying Cai et al. · Environmental Pollution · 2011 · 60 citations
György Székely, Bruno Henriques, M. Gil et al. · Journal of Pharmaceutical and Biomedical Analysis · 2012 · 54 citations
Pharmacy, Pharmacology, Toxicology +16
1–5 of 22
121
1
h-index
National Institute of Pharmaceutical Education and Research, India
1 publications · 26 citations
1
h-index
1
h-index
1
h-index
Instituto Nacional de Metrologia, Qualidade e Tecnologia, Brazil
1 publications · 11 citations
1
h-index
1–5 of 121
53
Eli Lilly (United States)
Indianapolis, United States
2 h-index
9 publications
138 citations

Ghent University
Ghent, Belgium
1 h-index
2 publications
80 citations
Regulatory Agency for Electronic Communications and Postal Services
Belgrade, Serbia
1 h-index
1 publications
21 citations
Industrial Research Institute
Arlington, United States
1 h-index
2 publications
36 citations

Karolinska Institutet
Stockholm, Sweden
1 h-index
2 publications
82 citations
University of Jordan
Amman, Jordan
1 h-index
1 publications
28 citations

Amersham Hospital
Amersham, United Kingdom
1 h-index
1 publications
41 citations
Institute of Inorganic Chemistry of the Slovak Academy of Sciences
Bratislava, Slovakia
1 h-index
4 publications
92 citations
1–8 of 53
7 publications · 181 citations
7
h-index
2 publications · 144 citations
2
h-index
1 publications · 18 citations
1
h-index
1 publications · 23 citations
1
h-index
1 publications · 21 citations
1
h-index
1–5